Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albrex is an oral anthelmintic medication containing the small molecule albendazole, manufactured by Medimet Pharmaceuticals. It belongs to the benzimidazole class of drugs and exerts its therapeutic effect by binding to the colchicine-sensitive site of parasite beta-tubulin. This binding inhibits tubulin polymerization into microtubules, leading to the disruption of essential cellular processes such as glucose uptake and secretion in the parasite, eventually resulting in its death. Albrex is indicated for the treatment of a variety of parasitic infestations, including intestinal nematode infections (such as ascariasis and hookworm) and systemic infections like hydatid disease caused by Echinococcus granulosus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albrex.